SMA ASO Candidates
Spinal Muscular Atrophy
Key Facts
About Biogen
Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.
View full company profileTherapeutic Areas
Other Spinal Muscular Atrophy Drugs
| Drug | Company | Phase |
|---|---|---|
| Spinal Muscular Atrophy (Skeletal Muscle) | Myocea | Research |
| Evrysdi (Risdiplam) | Roche | Approved |
| SMA Diagnostic Test | Genomics BioSci & Tech | Clinical |